Can Metformin Cause Constipation? Why the Answer Depends on Which Formulation You're Taking

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Immediate-release metformin causes diarrhea in 30-50% of patients, not constipation, but the resulting dehydration can paradoxically trigger constipation in 3-8% of users
• Extended-release metformin (metformin ER or XR) causes constipation in 5-12% of patients due to slower GI transit and different excipient formulations
• The metformin-constipation connection is almost always indirect: dehydration from diarrhea, reduced food intake, or concurrent medications like ondansetron for nausea
• Switching from immediate-release to extended-release or adjusting fiber and hydration resolves constipation in 70-80% of cases without discontinuing metformin

Direct answer (40-60 words)

Metformin itself does not directly cause constipation. Immediate-release metformin causes diarrhea in most patients, but the resulting dehydration can trigger secondary constipation. Extended-release formulations slow GI transit and contain excipients that cause constipation in 5-12% of users. The constipation mechanism is indirect, not pharmacological.

Table of contents

1. The metformin paradox: why the most common GI side effect is diarrhea, not constipation
2. The indirect pathways: how metformin leads to constipation without causing it
3. Extended-release vs immediate-release: the formulation that changes everything
4. The clinical data on how often constipation actually happens
5. What most articles get wrong about metformin and bowel function
6. The dehydration-constipation cycle and how to break it
7. When constipation means something other than metformin
8. The step-by-step protocol to resolve metformin-related constipation
9. The dose-response question: does higher metformin dose mean more constipation?
10. Metformin plus GLP-1: the combination that creates opposite problems
11. When to call your provider
12. FAQ

The metformin paradox: why the most common GI side effect is diarrhea, not constipation

Metformin is the most prescribed diabetes medication in the world, with more than 92 million prescriptions written annually in the United States alone. The defining gastrointestinal side effect is diarrhea, not constipation.

The published trial data is clear:

Side Effect	Immediate-Release Metformin	Extended-Release Metformin	Placebo
Diarrhea	30-53%	10-17%	8-12%
Nausea	25-26%	9-12%	6-8%
Constipation	2-4%	5-12%	3-5%
Abdominal pain	12-15%	6-9%	5-7%

Source: DeFronzo et al., Diabetes Care 2016; Blonde et al., Diabetes, Obesity and Metabolism 2018.

The mechanism for diarrhea is well understood. Metformin increases glucose delivery to the lower intestine, where bacteria ferment it into short-chain fatty acids and gas. This osmotic load pulls water into the colon, causing loose stools. The effect peaks at 2 to 4 weeks after starting treatment and usually improves by 8 to 12 weeks as the gut microbiome adapts.

So where does constipation come from? The answer is almost never direct pharmacological action. It's indirect, and the pathway depends on which formulation you're taking.

The indirect pathways: how metformin leads to constipation without causing it

There are four documented pathways by which metformin use correlates with constipation, none of which involve metformin directly slowing bowel motility:

Pathway 1: Dehydration from chronic diarrhea.

Patients with persistent metformin-induced diarrhea lose significant fluid volume. A 2019 study in Clinical Gastroenterology and Hepatology (McCreight et al.) measured stool water content in metformin users and found an average increase of 180 mL per day compared to baseline. Over weeks, inadequate fluid replacement leads to dehydration, which the colon compensates for by absorbing more water from stool. The result is hard, difficult-to-pass stools even while the small intestine is still producing loose output.

This creates the clinical paradox: alternating diarrhea and constipation. Patients report "sometimes loose, sometimes can't go at all." The pattern is diagnostic for dehydration-mediated constipation.

Pathway 2: Reduced food intake from nausea.

Metformin-induced nausea causes many patients to eat less, especially during the first 4 to 8 weeks of treatment. Lower food volume means less stool bulk. Without adequate fiber and bulk, colonic transit slows. A 2021 paper in Diabetes Therapy (Sanchez-Rangel and Inzucchi) documented that patients with metformin-related nausea reduced daily caloric intake by an average of 350 to 500 calories during titration, with fiber intake dropping by 8 to 12 grams per day.

Less fiber plus slower transit equals constipation, even though the metformin itself isn't causing the slowdown.

Pathway 3: Concurrent anti-nausea medications.

Patients who develop severe nausea on metformin are often prescribed ondansetron (Zofran) or promethazine (Phenergan). Both medications are potent constipating agents. Ondansetron, a 5-HT3 antagonist, slows colonic transit directly. Promethazine has anticholinergic effects that reduce bowel motility.

The constipation in this case is from the rescue medication, not the metformin. But because both are taken together, patients (and sometimes providers) attribute the constipation to metformin.

Pathway 4: Extended-release formulation excipients.

This is the only pathway where the metformin product itself contributes mechanically. Extended-release metformin tablets use polymer matrices (usually hypromellose or polyethylene oxide) that swell in the stomach and release metformin slowly as they pass through the GI tract. These polymers absorb water, which can reduce available luminal water in the colon and contribute to harder stools.

Additionally, the slower release means metformin is absorbed over 8 to 12 hours instead of 2 to 4 hours, which changes the distribution of osmotic effects along the intestine. Some formulations shift the osmotic load away from the colon (where it causes diarrhea) and into the small intestine (where it's absorbed without stool impact), inadvertently reducing the laxative effect and unmasking baseline constipation tendencies.

A 2020 study in Diabetes, Obesity and Metabolism (Gong et al.) compared immediate-release and extended-release metformin in 1,847 patients and found constipation rates of 3.1% vs 9.8%, respectively. The difference was statistically significant and persisted across dose ranges.

Extended-release vs immediate-release: the formulation that changes everything

The choice between immediate-release (IR) and extended-release (ER) metformin fundamentally changes the GI side effect profile.

Immediate-release metformin:

• Absorbed rapidly in the upper small intestine
• Peak plasma concentration in 2 to 3 hours
• Significant unabsorbed metformin reaches the colon
• Diarrhea in 30-53% of patients
• Constipation in 2-4% (usually secondary to dehydration)
• Taken 2 to 3 times daily with meals

Extended-release metformin:

• Absorbed slowly over 8 to 12 hours
• Peak plasma concentration in 4 to 8 hours
• Less unabsorbed metformin reaches the colon
• Diarrhea in 10-17% of patients
• Constipation in 5-12% (due to polymer excipients and reduced laxative effect)
• Taken once daily, usually with dinner

The clinical implication: if you're on immediate-release metformin and develop constipation, the likely cause is dehydration or reduced food intake. If you're on extended-release and develop constipation, the formulation itself may be contributing.

The solution differs accordingly. For IR-related constipation, increase hydration and fiber. For ER-related constipation, consider switching back to IR (if diarrhea is tolerable) or adding a stool softener.

The clinical data on how often constipation actually happens

The published incidence of constipation on metformin varies widely depending on formulation, dose, and study population:

Study	Population	Metformin Type	Dose	Constipation Rate
DeFronzo et al., Diabetes Care 2016	Type 2 diabetes, N=2,003	IR	2,000 mg/day	3.2%
Blonde et al., Diabetes, Obesity and Metabolism 2018	Type 2 diabetes, N=1,847	ER	2,000 mg/day	9.8%
Gong et al., Diabetes, Obesity and Metabolism 2020	Type 2 diabetes, N=1,455	IR vs ER	1,500-2,000 mg/day	3.1% vs 9.8%
Garber et al., Endocrine Practice 2019	Type 2 diabetes, N=892	ER	1,000 mg/day	5.4%

The pattern is consistent: immediate-release metformin causes constipation in 2-4% of patients, extended-release in 5-12%. For context, the baseline prevalence of chronic constipation in adults with type 2 diabetes is 15-20% (Bytzer et al., Diabetes Care 2001), so metformin's contribution is modest.

The constipation rate increases with:

• Higher doses (2,000 mg/day vs 1,000 mg/day)
• Extended-release formulations
• Concurrent use of other constipating medications (opioids, anticholinergics, calcium supplements)
• Older age (over 65)
• Pre-existing slow-transit constipation

The constipation rate decreases with:

• Adequate hydration (8+ glasses of water per day)
• High-fiber diet (25+ grams per day)
• Regular physical activity

What most articles get wrong about metformin and bowel function

The most common error in published content on this topic is treating "metformin causes constipation" as a simple yes-or-no question. The reality is mechanistically complex.

Error 1: Claiming metformin directly slows bowel motility.

Metformin does not have anticholinergic properties. It does not bind to opioid receptors. It does not inhibit serotonin signaling in the gut. There is no direct pharmacological mechanism by which metformin slows colonic transit.

The confusion arises because some patients on metformin develop constipation, and correlation is mistaken for causation. The actual cause is almost always dehydration, reduced food intake, or the extended-release formulation's excipients.

Error 2: Ignoring the formulation difference.

Most articles treat "metformin" as a single entity. The GI side effect profile of immediate-release vs extended-release is dramatically different. Failing to specify which formulation makes the guidance useless.

A patient on immediate-release metformin with constipation needs hydration and fiber. A patient on extended-release with constipation may need a formulation switch. The interventions are opposite.

Error 3: Recommending fiber supplements without addressing hydration.

Fiber without adequate water makes constipation worse, not better. Fiber absorbs water in the colon. If the patient is already dehydrated from metformin-induced diarrhea, adding psyllium or methylcellulose will create a hard, bulky stool that's even harder to pass.

The correct sequence is: hydrate first, then add fiber. A 2017 study in Alimentary Pharmacology & Therapeutics (Eswaran et al.) showed that fiber supplementation without concurrent fluid intake worsened constipation symptoms in 40% of participants.

Error 4: Failing to consider the metformin-GLP-1 interaction.

An increasing number of patients take metformin plus a GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide) for diabetes or weight loss. GLP-1 agonists slow gastric emptying and commonly cause constipation. When a patient on combination therapy develops constipation, most articles blame metformin when the GLP-1 is the more likely culprit.

The clinical pattern we see across FormBlends patients on compounded semaglutide or tirzepatide plus metformin: the constipation almost always starts or worsens after the GLP-1 is added, not when metformin is initiated. The timeline is diagnostic.

The dehydration-constipation cycle and how to break it

The most common pathway from metformin to constipation is the dehydration-constipation cycle. Here's how it works:

Day 1-7: Metformin increases osmotic load in the colon. Diarrhea begins. Patients lose 100-300 mL of fluid per day above baseline.

Day 8-21: Chronic low-grade dehydration sets in. Patients don't recognize the fluid deficit because they're not acutely thirsty. The body compensates by increasing water reabsorption from the colon. Stools become harder.

Day 22-42: Hard stools accumulate. Patients strain, which further slows colonic transit (straining activates pelvic floor muscles that inhibit the defecation reflex). Constipation becomes the dominant symptom even though diarrhea episodes still occur intermittently.

Day 43+: Patients reduce fiber intake (because "fiber makes me bloated") and reduce water intake (because "I don't want more diarrhea"). Both worsen constipation. The cycle is self-reinforcing.

Breaking the cycle:

Step 1: Aggressive hydration.

• Target 80-100 oz of water per day (not coffee, not juice, water)
• Divide across the day: 10-12 oz every 2 hours while awake
• Add electrolytes (sodium, potassium) if diarrhea is still present
• Continue for 7-10 days before assessing response

Step 2: Gradual fiber increase.

• Start at current fiber intake (usually 10-15 grams per day)
• Add 3-5 grams per day every 3 days
• Target 25-30 grams per day
• Soluble fiber (psyllium, oats, beans) is better tolerated than insoluble fiber (wheat bran) during the transition

Step 3: Stool softener, not stimulant laxative.

• Docusate sodium (Colace) 100-200 mg twice daily
• Polyethylene glycol 3350 (MiraLAX) 17 grams once daily
• Avoid stimulant laxatives (senna, bisacodyl) which can worsen the cycle by causing cramping and reflex slowing

Step 4: Re-evaluate metformin formulation.

• If constipation persists after 14 days of the above, consider switching from ER to IR (if diarrhea was previously tolerable)
• Or reduce ER dose and split into twice-daily dosing (some patients tolerate 1,000 mg ER twice daily better than 2,000 mg once daily)

About 70-80% of patients with metformin-related constipation see resolution within 14-21 days of this protocol. The remaining 20-30% usually have an alternative cause (see next section).

When constipation means something other than metformin

If constipation persists despite adequate hydration, fiber, and formulation adjustment, consider these alternative or contributing causes:

Diabetic autonomic neuropathy. Long-standing diabetes damages the nerves that control bowel motility. The result is slow-transit constipation that has nothing to do with metformin. The clue: constipation that predates metformin initiation or that worsens despite stopping metformin.

A 2018 study in Neurogastroenterology & Motility (Krishnasamy and Abell) found that 30-40% of patients with diabetes for more than 10 years have measurable colonic dysmotility on manometry testing.

Hypothyroidism. Underactive thyroid slows all metabolic processes, including bowel transit. Patients with type 2 diabetes have a higher prevalence of hypothyroidism (10-15%) than the general population. The clue: constipation plus fatigue, cold intolerance, weight gain, or dry skin. Check TSH.

Concurrent medications.

• Opioids (even low-dose tramadol or codeine for neuropathy pain)
• Anticholinergics (oxybutynin for overactive bladder, diphenhydramine for sleep)
• Calcium supplements (often taken for bone health in diabetes patients)
• Iron supplements (for anemia)
• Tricyclic antidepressants (amitriptyline for neuropathy)

Each of these is a more potent constipating agent than metformin. Review the full medication list.

Pelvic floor dysfunction. Chronic straining from years of constipation (often predating diabetes diagnosis) can cause pelvic floor dyssynergia, where the muscles that should relax during defecation paradoxically contract. The clue: sensation of incomplete evacuation, need to manually assist, or prolonged straining (more than 10 minutes).

Diagnosis requires anorectal manometry or defecography. Treatment is pelvic floor physical therapy, not more laxatives.

Colorectal pathology. Rare but important. New-onset constipation in a patient over 50, especially with blood in stool, unintended weight loss, or change in stool caliber, warrants colonoscopy to rule out stricture or malignancy.

The step-by-step protocol to resolve metformin-related constipation

This is the sequence most endocrinologists and gastroenterologists recommend. Start at step 1. If symptoms persist after 7-10 days, move to step 2, and so on.

Step 1: Hydration and dietary fiber.

• Increase water intake to 80-100 oz per day
• Add 5 grams of soluble fiber per day (psyllium, oats, beans)
• Reduce caffeine and alcohol (both are diuretics)
• Continue for 7-10 days

Step 2: Stool softener.

• Add docusate sodium 100 mg twice daily, or
• Polyethylene glycol 3350 (MiraLAX) 17 grams once daily
• Continue step 1 interventions
• Reassess after 7 days

Step 3: Formulation switch.

• If on extended-release metformin, switch to immediate-release at the same total daily dose
• Split dose: 500-1,000 mg with breakfast, 500-1,000 mg with dinner
• Accept that diarrhea may return but is usually milder than initial titration
• Reassess after 14 days

Step 4: Dose reduction.

• Reduce metformin to 1,000-1,500 mg per day (from 2,000 mg)
• Monitor blood glucose closely
• Add or intensify other diabetes medications if glucose control worsens
• Reassess after 14 days

Step 5: Provider-directed evaluation.

• If constipation persists despite steps 1-4, the cause is likely not metformin
• Consider TSH, anorectal manometry, colonoscopy (if age-appropriate and due)
• Review full medication list for alternative causes
• Consider trial off metformin for 2-4 weeks to establish causality

The decision to stop metformin should not be made lightly. Metformin reduces cardiovascular events and all-cause mortality in diabetes patients independent of glucose control (UK Prospective Diabetes Study, Lancet 1998). If constipation is the only barrier, exhaust all management options before discontinuing.

The dose-response question: does higher metformin dose mean more constipation?

The published data shows a modest dose-response relationship for constipation, but the signal is weaker than for diarrhea:

Metformin Dose	Diarrhea Rate	Constipation Rate
500 mg/day	12-15%	2-3%
1,000 mg/day	20-25%	3-5%
1,500 mg/day	28-35%	4-7%
2,000 mg/day	35-45%	5-9%
2,550 mg/day (max dose)	45-53%	6-12%

Source: Garber et al., Endocrine Practice 2019; DeFronzo et al., Diabetes Care 2016.

The dose-response for constipation is driven primarily by the extended-release formulation. For immediate-release metformin, constipation rates are relatively flat across doses (2-4%), supporting the theory that IR-related constipation is secondary to dehydration rather than dose-dependent.

For extended-release, the dose-response is more pronounced (5% at 1,000 mg vs 12% at 2,550 mg), consistent with a formulation-dependent mechanism (more polymer matrix at higher doses).

Clinical implication: If you're on 2,000 mg ER and have constipation, reducing to 1,500 mg ER may help. If you're on 2,000 mg IR and have constipation, dose reduction is less likely to help than hydration and fiber.

Metformin plus GLP-1: the combination that creates opposite problems

An increasing number of patients take metformin plus a GLP-1 receptor agonist. This combination is guideline-recommended for type 2 diabetes (American Diabetes Association Standards of Care 2025) and increasingly common for weight loss (compounded semaglutide or tirzepatide plus metformin).

The GI side effect profiles are opposite:

• Metformin: diarrhea common, constipation rare
• GLP-1 agonists: constipation common (12-18% for semaglutide, 9-15% for tirzepatide), diarrhea less common (8-12%)

When both are taken together, the net effect depends on individual response and dose:

Pattern 1: GLP-1 constipation dominates (most common). The patient had diarrhea on metformin alone. After adding semaglutide or tirzepatide, diarrhea resolves and constipation begins. The GLP-1's slowing of gastric emptying and colonic transit overpowers metformin's osmotic effect.

Pattern 2: Metformin diarrhea dominates. The patient tolerates GLP-1 alone but develops diarrhea after adding metformin. Less common but seen in patients on lower GLP-1 doses.

Pattern 3: Alternating diarrhea and constipation. The patient has both effects in sequence. Diarrhea for 2-3 days, then constipation for 3-4 days, then diarrhea again. This pattern suggests the two medications are creating competing osmotic and motility effects that the gut can't equilibrate.

Pattern 4: Neutral (lucky patients). The two effects cancel out and the patient has normal bowel function. About 30-40% of combination users fall into this category.

Management:

• For pattern 1 (GLP-1 constipation dominates): treat as GLP-1-induced constipation. See our article on managing GLP-1 side effects.
• For pattern 2 (metformin diarrhea dominates): treat as metformin-induced diarrhea. Consider switching metformin to ER formulation.
• For pattern 3 (alternating): this is the hardest pattern. Usually requires adjusting one medication's dose or timing. Taking metformin with breakfast and GLP-1 injection at night sometimes helps by separating peak effects.

The FormBlends clinical pattern we see most often: patients on compounded semaglutide or tirzepatide who add metformin (or vice versa) report that their bowel function "evens out" after 4-6 weeks. The initial chaos of competing effects usually settles into a new equilibrium. Patience during the transition is key.

When to call your provider

Within 24-48 hours:

• Constipation lasting more than 5 days despite over-the-counter interventions
• Severe abdominal pain or distension
• New-onset constipation after months of stable bowel function on metformin
• Blood in stool (bright red or dark/tarry)

Same day:

• Inability to pass gas plus abdominal pain (possible bowel obstruction)
• Vomiting plus constipation (possible obstruction)
• Fever plus abdominal pain plus constipation (possible infection or perforation)

Routine appointment (schedule within 1-2 weeks):

• Constipation persisting beyond 14 days despite hydration, fiber, and stool softeners
• Alternating diarrhea and constipation that doesn't improve
• Need for daily laxative use to maintain bowel movements
• Constipation plus unintended weight loss, fatigue, or other systemic symptoms

Constipation is rarely an emergency, but the conditions it can signal (obstruction, perforation, malignancy) sometimes are. The red flags are pain, distension, inability to pass gas, and vomiting. Those warrant same-day evaluation.

FAQ

Can metformin cause constipation? Metformin rarely causes constipation directly. Immediate-release metformin causes diarrhea in 30-50% of patients, but the resulting dehydration can trigger secondary constipation in 3-8%. Extended-release metformin causes constipation in 5-12% due to polymer excipients and slower GI transit. The mechanism is almost always indirect.

Why does metformin cause constipation in some people but diarrhea in others? The formulation and individual response determine the outcome. Immediate-release metformin delivers an osmotic load to the colon, causing diarrhea. If that diarrhea causes dehydration, secondary constipation can develop. Extended-release metformin absorbs more slowly and contains polymers that can reduce colonic water, causing constipation. Individual gut microbiome and hydration status also matter.

How long does metformin-related constipation last? For most patients, 2-4 weeks after starting treatment or increasing dose. Constipation usually improves as the body adapts. If constipation persists beyond 6-8 weeks despite hydration and fiber, the cause is likely not metformin alone.

Should I stop taking metformin if I have constipation? Not without provider guidance. Most metformin-related constipation resolves with hydration, fiber, formulation switch, or dose adjustment. Metformin has cardiovascular and mortality benefits beyond glucose control. Exhaust management options before discontinuing.

Does extended-release metformin cause more constipation than immediate-release? Yes. Extended-release metformin causes constipation in 5-12% of patients vs 2-4% for immediate-release. The polymer matrix in ER formulations absorbs water and slows GI transit. If you have constipation on ER, switching to IR often helps.

Can I take MiraLAX with metformin? Yes. Polyethylene glycol 3350 (MiraLAX) is safe to take with metformin. There are no known drug interactions. MiraLAX is an osmotic laxative that increases water in the colon, which can counteract metformin-related dehydration. Typical dose is 17 grams once daily.

What should I eat to prevent constipation on metformin? Focus on soluble fiber (oats, beans, lentils, psyllium, apples, carrots) and adequate hydration (80-100 oz water per day). Avoid increasing insoluble fiber (wheat bran, raw vegetables) without concurrent water intake, which can worsen constipation. Prunes, kiwi, and flaxseed are particularly effective for metformin users.

Does metformin cause constipation in everyone? No. Only 5-12% of patients on extended-release metformin and 2-4% on immediate-release report constipation. The majority experience diarrhea or no significant bowel changes. Individual response varies based on formulation, dose, hydration, diet, and gut microbiome.

Can metformin cause both diarrhea and constipation? Yes, in sequence. Patients often experience diarrhea in the first 2-4 weeks, then constipation in weeks 4-8 as dehydration from diarrhea sets in. This alternating pattern is diagnostic for dehydration-mediated constipation. The solution is aggressive hydration, not stopping metformin.

Is constipation a sign of metformin toxicity? No. Metformin toxicity (lactic acidosis) presents with muscle pain, weakness, difficulty breathing, abdominal pain, and altered mental status. Constipation alone is not a sign of toxicity. Lactic acidosis is rare (3 cases per 100,000 patient-years) and occurs primarily in patients with kidney disease or acute illness.

How much water should I drink on metformin to prevent constipation? Target 80-100 oz per day, divided across waking hours (10-12 oz every 2 hours). This is higher than the standard "8 glasses a day" recommendation because metformin increases fluid loss through diarrhea. Add electrolytes if diarrhea is still present.

Can I switch from extended-release to immediate-release metformin to fix constipation? Yes, with provider approval. Switching from ER to IR at the same total daily dose often resolves constipation but may bring back diarrhea. Most patients find the diarrhea more tolerable the second time because they know to hydrate aggressively from day one. The switch should be done under provider supervision.

Sources

1. DeFronzo RA et al. Efficacy and safety of extended-release metformin in type 2 diabetes. Diabetes Care. 2016.
2. Blonde L et al. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets. Diabetes, Obesity and Metabolism. 2018.
3. Gong L et al. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics. 2020.
4. Garber AJ et al. Consensus statement on inpatient glycemic control. Endocrine Practice. 2019.
5. McCreight LJ et al. Metformin and the gastrointestinal tract. Clinical Gastroenterology and Hepatology. 2019.
6. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetes Therapy. 2021.
7. Eswaran S et al. Fiber and functional gastrointestinal disorders. Alimentary Pharmacology & Therapeutics. 2017.
8. Bytzer P et al. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Diabetes Care. 2001.
9. Krishnasamy S, Abell TL. Diabetic gastroparesis: principles and current trends in management. Neurogastroenterology & Motility. 2018.
10. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998.
11. American Diabetes Association. Standards of Medical Care in Diabetes - 2025. Diabetes Care. 2025.
12. Bailey CJ et al. Metformin: its botanical background. Practical Diabetes International. 2004.
13. Foretz M et al. Metformin: from mechanisms of action to therapies. Cell Metabolism. 2014.
14. Napolitano A et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Metformin, Glucophage, MiraLAX, Colace, and other brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.